PRDS
PRDS 40 articles

Pardes Biosciences Announces Closing of Tender Offer

globenewswire.com·Aug 31

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

businesswire.com·Aug 28

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 19

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 18

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

businesswire.com·Aug 17

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 9

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 8

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

businesswire.com·Aug 7

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 6

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 5

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 4

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 3

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Aug 1

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Jul 31

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

accesswire.com·Jul 29

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Jul 25

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Jul 24

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

businesswire.com·Jul 21

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Jul 20

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

businesswire.com·Jul 19

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

accesswire.com·Jul 19

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

accesswire.com·Jul 18

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

·Jul 17

Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

·Jul 17

Pardes Biosciences stock rallies on buyout offer from MediPacific

·Jul 17

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

·Jul 17

All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy

zacks.com·Jun 5

Pardes Biosciences Seeking Strategic Alternatives

seekingalpha.com·May 17

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

globenewswire.com·Feb 1

10 Top Penny Stocks To Watch With High Short Interest This Week

pennystocks.com·Jan 31

Pardes Biosciences to Present at Jefferies London Healthcare Conference

globenewswire.com·Nov 1

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

globenewswire.com·Sep 12

Pardes Biosciences to Present at Jefferies Global Healthcare Conference

globenewswire.com·Jun 1

Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

globenewswire.com·Mar 21

Pardes Biosciences to Present at Cowen Healthcare Conference

globenewswire.com·Mar 3

Pardes Biosciences Shares Early Data From COVID-19 Study

benzinga.com·Feb 14

Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022

globenewswire.com·Feb 8

Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19

benzinga.com·Feb 3

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

seekingalpha.com·Jan 21

Pardes Biosciences to Present at J.P. Morgan Healthcare Conference

globenewswire.com·Jan 5
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.